mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

BNT164a1 - BioNTech

BNT164b1 - BioNTech

http://www.ncbi.nlm.nih.gov/pubmed/42286358

Annette B Vogel; Anuhar Chaturvedi; Charles L Dulberger; Jan Diekmann; Janina Vogt; Louis S Ates; Mustafa Diken; Natasa Vukovic; Neha Agrawal; Stefan A Schille

Jun 13, 2026